Delayed
NSE India S.E.
03:14:20 29/04/2024 pm IST
|
5-day change
|
1st Jan Change
|
244.5
INR
|
-4.99%
|
|
-22.61%
|
-14.75%
|
Fiscal Period: March |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
94,683
|
50,073
|
25,274
|
37,250
|
80,734
|
58,203
|
Enterprise Value (EV)
1 |
93,628
|
47,980
|
25,869
|
39,457
|
81,398
|
54,335
|
P/E ratio
|
-47.5
x
|
-33.6
x
|
-8.09
x
|
-24.6
x
|
-38.4
x
|
-22.9
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
121
x
|
27.4
x
|
32.9
x
|
14.7
x
|
58.8
x
|
24.4
x
|
EV / Revenue
|
120
x
|
26.2
x
|
33.7
x
|
15.6
x
|
59.3
x
|
22.8
x
|
EV / EBITDA
|
-38.6
x
|
-33.2
x
|
-8.42
x
|
-28.9
x
|
-43.4
x
|
-25.3
x
|
EV / FCF
|
-60.3
x
|
-47.7
x
|
-14.7
x
|
-34.9
x
|
-44.4
x
|
-88.9
x
|
FCF Yield
|
-1.66%
|
-2.09%
|
-6.81%
|
-2.86%
|
-2.25%
|
-1.13%
|
Price to Book
|
51.3
x
|
16.9
x
|
-136
x
|
-22.1
x
|
259
x
|
11.4
x
|
Nbr of stocks (in thousands)
|
2,50,914
|
2,62,025
|
2,62,048
|
2,62,048
|
2,71,879
|
3,24,522
|
Reference price
2 |
377.4
|
191.1
|
96.45
|
142.2
|
297.0
|
179.4
|
Announcement Date
|
01/08/18
|
05/07/19
|
07/09/20
|
07/09/21
|
30/08/22
|
14/07/23
|
Fiscal Period: March |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
782.6
|
1,829
|
768.1
|
2,530
|
1,372
|
2,388
|
EBITDA
1 |
-2,426
|
-1,446
|
-3,072
|
-1,366
|
-1,877
|
-2,149
|
EBIT
1 |
-2,508
|
-1,521
|
-3,150
|
-1,457
|
-1,961
|
-2,236
|
Operating Margin
|
-320.44%
|
-83.18%
|
-410.02%
|
-57.6%
|
-142.86%
|
-93.66%
|
Earnings before Tax (EBT)
1 |
-1,970
|
-1,454
|
-3,124
|
-1,511
|
-2,034
|
-2,226
|
Net income
1 |
-1,970
|
-1,454
|
-3,124
|
-1,511
|
-2,034
|
-2,226
|
Net margin
|
-251.73%
|
-79.53%
|
-406.7%
|
-59.75%
|
-148.19%
|
-93.22%
|
EPS
2 |
-7.941
|
-5.690
|
-11.92
|
-5.768
|
-7.729
|
-7.818
|
Free Cash Flow
1 |
-1,553
|
-1,005
|
-1,761
|
-1,130
|
-1,833
|
-611.5
|
FCF margin
|
-198.41%
|
-54.95%
|
-229.23%
|
-44.69%
|
-133.56%
|
-25.61%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
01/08/18
|
05/07/19
|
07/09/20
|
07/09/21
|
30/08/22
|
14/07/23
|
Fiscal Period: March |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
-
|
-
|
595
|
2,207
|
663
|
-
|
Net Cash position
1 |
1,055
|
2,093
|
-
|
-
|
-
|
3,868
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-0.1937
x
|
-1.615
x
|
-0.3533
x
|
-
|
Free Cash Flow
1 |
-1,553
|
-1,005
|
-1,761
|
-1,130
|
-1,833
|
-612
|
ROE (net income / shareholders' equity)
|
-115%
|
-60.5%
|
-225%
|
162%
|
297%
|
-81.8%
|
ROA (Net income/ Total Assets)
|
-53.9%
|
-26.9%
|
-58.7%
|
-36.3%
|
-48.1%
|
-25.2%
|
Assets
1 |
3,654
|
5,410
|
5,325
|
4,168
|
4,230
|
8,840
|
Book Value Per Share
2 |
7.360
|
11.30
|
-0.7100
|
-6.420
|
1.150
|
15.80
|
Cash Flow per Share
2 |
0.0100
|
0.0100
|
0.0100
|
0.3600
|
0.0500
|
0.0200
|
Capex
1 |
326
|
130
|
540
|
60
|
327
|
154
|
Capex / Sales
|
41.7%
|
7.08%
|
70.35%
|
2.37%
|
23.81%
|
6.44%
|
Announcement Date
|
01/08/18
|
05/07/19
|
07/09/20
|
07/09/21
|
30/08/22
|
14/07/23
|
|
1st Jan change
|
Capi.
|
---|
| -14.75% | 1B | | +25.83% | 661B | | +26.72% | 566B | | -6.76% | 352B | | +20.34% | 332B | | +3.00% | 283B | | +14.75% | 231B | | +5.00% | 200B | | -9.08% | 195B | | -6.26% | 145B |
Other Pharmaceuticals
|